The effectiveness and tolerability of psychotropic medications are profoundly influenced by their dosage formulation. Beyond the active ingredient, the drug delivery system plays a critical role in optimizing pharmacokinetics, improving adherence, and managing side effects. From orally disintegrating tablets that prevent “cheeking” to long-acting injectables that solve adherence challenges, understanding these formulations is a key pharmacy skill. This quiz will test your knowledge on the various dosage forms used for psychotropic drugs and the clinical rationale behind their use.
1. A major advantage of an Orally Disintegrating Tablet (ODT) formulation for an antipsychotic is:
- a. It provides a longer duration of action.
- b. It prevents patients from “cheeking” and later spitting out the medication.
- c. It has a better taste than the standard tablet.
- d. It is less expensive to manufacture.
Answer: b. It prevents patients from “cheeking” and later spitting out the medication.
2. A patient is prescribed olanzapine as a short-acting intramuscular (IM) injection. What is the most likely clinical scenario for its use?
- a. For long-term, once-monthly maintenance therapy.
- b. For the management of acute agitation.
- c. For a patient who cannot swallow pills.
- d. As a first-line treatment for depression.
Answer: b. For the management of acute agitation.
3. Long-Acting Injectable (LAI) antipsychotics are primarily designed to:
- a. Provide a faster onset of action than oral tablets.
- b. Improve medication adherence for patients with chronic psychotic disorders.
- c. Eliminate all side effects of the medication.
- d. Be administered intravenously by the patient at home.
Answer: b. Improve medication adherence for patients with chronic psychotic disorders.
4. A patient is prescribed paliperidone palmitate. The pharmacist recognizes this as a long-acting injectable that is administered:
- a. Once a week
- b. Every two weeks
- c. Once a month
- d. Once every three months
Answer: c. Once a month
5. Which of the following is a common vehicle used for long-acting depot injections of antipsychotics?
- a. Sterile water
- b. An oily (oleaginous) vehicle
- c. An alcohol-based solution
- d. A saline solution
Answer: b. An oily (oleaginous) vehicle
6. A key counseling point for a patient receiving an LAI antipsychotic is:
- a. The importance of returning to the clinic on schedule for their next injection.
- b. That they can miss a dose by several weeks without consequence.
- c. That the injection will cure their illness.
- d. To massage the injection site vigorously to speed up absorption.
Answer: a. The importance of returning to the clinic on schedule for their next injection.
7. A patient is prescribed an SSRI as an oral solution instead of a tablet. A likely reason for this is:
- a. The patient has dysphagia (difficulty swallowing).
- b. The oral solution has a faster onset of action.
- c. The oral solution has fewer side effects.
- d. The oral solution is less expensive.
Answer: a. The patient has dysphagia (difficulty swallowing).
8. Why must an oral overlap be provided when starting most LAI antipsychotics?
- a. To increase the total dose of the antipsychotic.
- b. To reach therapeutic concentrations of the LAI, which can take several weeks.
- c. It is not necessary to provide an overlap.
- d. To treat injection site reactions.
Answer: b. To reach therapeutic concentrations of the LAI, which can take several weeks.
9. The use of extended-release (XR/ER) formulations for psychotropic drugs like quetiapine or venlafaxine is designed to:
- a. Allow for once-daily dosing and potentially reduce side effects.
- b. Provide a more rapid peak concentration.
- c. Make the tablets easier to crush.
- d. Increase the total amount of drug absorbed.
Answer: a. Allow for once-daily dosing and potentially reduce side effects.
10. A patient is prescribed the Risperdal Consta LAI. This formulation uses what technology to achieve its long duration of action?
- a. An oily vehicle
- b. Encapsulation of the drug in biodegradable polymer microspheres.
- c. A crystal suspension.
- d. Attachment of a long fatty acid chain.
Answer: b. Encapsulation of the drug in biodegradable polymer microspheres.
11. A key counseling point for a patient prescribed an extended-release tablet is:
- a. The tablet can be crushed or chewed for faster effect.
- b. The tablet must be swallowed whole and not crushed or chewed.
- c. The tablet should be taken on an empty stomach.
- d. The patient may see the tablet “ghost” in their stool.
Answer: b. The tablet must be swallowed whole and not crushed or chewed.
12. A “sublingual” formulation of a drug like asenapine is designed to be:
- a. Swallowed with water.
- b. Placed under the tongue to dissolve and be absorbed directly into the bloodstream.
- c. Chewed thoroughly.
- d. Applied to the skin.
Answer: b. Placed under the tongue to dissolve and be absorbed directly into the bloodstream.
13. A major advantage of a sublingual or ODT formulation is that it:
- a. Has a longer half-life.
- b. Bypasses first-pass metabolism in the liver.
- c. Is more potent.
- d. Is available for all psychotropic drugs.
Answer: b. Bypasses first-pass metabolism in the liver.
14. A pharmacist’s role in managing these various formulations includes:
- a. Ensuring the patient understands the correct administration for their specific dosage form.
- b. Identifying if a different formulation could improve a patient’s adherence or tolerability.
- c. Counseling on the difference between short-acting and long-acting injections.
- d. All of the above.
Answer: d. All of the above.
15. A patient taking a once-daily extended-release medication for ADHD complains that it wears off before the end of the school day. The pharmacist could recognize this as a potential issue with:
- a. The drug’s formulation and duration of action.
- b. A lack of efficacy of the drug itself.
- c. A drug-drug interaction.
- d. Patient non-adherence.
Answer: a. The drug’s formulation and duration of action.
16. Which of the following is NOT an advantage of an LAI antipsychotic?
- a. Improved adherence
- b. Reduced risk of relapse
- c. Easy and immediate discontinuation of the drug if a serious side effect occurs.
- d. More predictable plasma concentrations.
Answer: c. Easy and immediate discontinuation of the drug if a serious side effect occurs.
17. Orally disintegrating tablets are a good option for patients who:
- a. Have difficulty swallowing (dysphagia).
- b. Might be “cheeking” their medication.
- c. Need a rapid onset of action.
- d. All of the above.
Answer: d. All of the above.
18. The “depot” in a depot injection refers to:
- a. The needle used for the injection.
- b. The area in the muscle where the drug is deposited and slowly released.
- c. The pharmacy where the injection is prepared.
- d. The brand name of the drug.
Answer: b. The area in the muscle where the drug is deposited and slowly released.
19. Which of the following is NOT a common dosage form for a psychotropic medication?
- a. Oral tablet
- b. Intravenous bolus for chronic maintenance
- c. Long-acting intramuscular injection
- d. Orally disintegrating tablet
Answer: b. Intravenous bolus for chronic maintenance
20. A key consideration when switching a patient from an oral antipsychotic to its LAI equivalent is:
- a. Using the correct conversion dose and initiation schedule.
- b. Ensuring the patient is tolerant of the oral formulation first.
- c. Both a and b.
- d. Neither a nor b.
Answer: c. Both a and b.
21. A patient complains that their extended-release capsule is appearing in their stool. The pharmacist should explain that:
- a. The medication is not working.
- b. This is a medical emergency.
- c. This is a normal occurrence known as a “ghost tablet,” and the medication has been properly absorbed.
- d. They should crush the capsules from now on.
Answer: c. This is a normal occurrence known as a “ghost tablet,” and the medication has been properly absorbed.
22. An intranasal spray formulation for a psychotropic drug would offer what potential advantage?
- a. A long duration of action.
- b. A very rapid onset of action due to absorption through the nasal mucosa.
- c. Lower cost.
- d. No side effects.
Answer: b. A very rapid onset of action due to absorption through the nasal mucosa.
23. The choice of dosage form can significantly impact a patient’s adherence.
- a. True
- b. False
Answer: a. True
24. A pharmacist must be knowledgeable about how to properly reconstitute and administer LAI formulations.
- a. True
- b. False
Answer: a. True
25. The ultimate reason for developing different dosage formulations of psychotropic drugs is to:
- a. Make the medications more expensive.
- b. Meet the diverse clinical needs of patients and improve treatment outcomes.
- c. Make the drugs more difficult to administer.
- d. Comply with a marketing request.
Answer: b. Meet the diverse clinical needs of patients and improve treatment outcomes.
26. A transdermal patch delivery system for a psychotropic drug (e.g., methylphenidate or selegiline) provides:
- a. Rapid, pulsatile drug delivery.
- b. Localized effect on the skin only.
- c. Continuous, systemic drug delivery over a prolonged period.
- d. A way to avoid all side effects.
Answer: c. Continuous, systemic drug delivery over a prolonged period.
27. What is a key counseling point for any transdermal patch?
- a. Apply it to the same spot every time.
- b. Cut the patch to adjust the dose.
- c. Rotate the application site to avoid skin irritation.
- d. Apply a heating pad over the patch to increase absorption.
Answer: c. Rotate the application site to avoid skin irritation.
28. An orally dissolving film (e.g., Suboxone) is a dosage form designed to:
- a. Be swallowed whole.
- b. Be applied to the skin.
- c. Dissolve on or under the tongue for transmucosal absorption.
- d. Be injected.
Answer: c. Dissolve on or under the tongue for transmucosal absorption.
29. The term “pharmacokinetics” refers to what the body does to the drug. A drug’s dosage form is a primary determinant of its pharmacokinetic profile.
- a. True
- b. False
Answer: a. True
30. A key advantage of an LAI is that it:
- a. Ensures the patient receives the medication for the duration of the injection interval.
- b. Is easy for patients to self-administer.
- c. Is painless.
- d. Works immediately.
Answer: a. Ensures the patient receives the medication for the duration of the injection interval.
31. The development of different dosage forms is a key topic in which field of study?
- a. Pharmaceutics and Drug Delivery
- b. Pharmacogenomics
- c. Medicinal Chemistry
- d. Toxicology
Answer: a. Pharmaceutics and Drug Delivery
32. A patient with severe nausea may benefit from which formulation of an antiemetic?
- a. A large oral tablet.
- b. An orally disintegrating tablet or a rectal suppository.
- c. An oral solution with a bad taste.
- d. A chewable tablet.
Answer: b. An orally disintegrating tablet or a rectal suppository.
33. The technology behind long-acting injectables often involves creating a “depot” in the muscle using:
- a. An oily vehicle.
- b. A polymer microsphere system.
- c. A drug crystal suspension.
- d. All of the above are possible technologies.
Answer: d. All of the above are possible technologies.
34. The pharmacist’s role includes identifying patients who might benefit from a change in dosage formulation.
- a. True
- b. False
Answer: a. True
35. A “sprinkle” capsule formulation is designed to:
- a. Be swallowed whole only.
- b. Be opened so the contents can be sprinkled on soft food for patients with dysphagia.
- c. Be dissolved in a carbonated beverage.
- d. Be used as a topical powder.
Answer: b. Be opened so the contents can be sprinkled on soft food for patients with dysphagia.
36. Why is adherence particularly critical for LAIs?
- a. If a patient misses their scheduled injection, they will be without medication for an extended period.
- b. The injections are very expensive.
- c. The injection site reactions are severe.
- d. It is not critical.
Answer: a. If a patient misses their scheduled injection, they will be without medication for an extended period.
37. Which of the following is NOT an advantage of an ODT?
- a. Useful for patients with difficulty swallowing.
- b. Rapid onset of action.
- c. Prevents “cheeking.”
- d. Provides a month-long duration of action.
Answer: d. Provides a month-long duration of action.
38. The choice of dosage form can be a key part of “patient-centered care.”
- a. True
- b. False
Answer: a. True
39. A key consideration for any long-acting formulation is:
- a. If an adverse effect occurs, the drug cannot be easily removed from the body.
- b. It is easy to stop the therapy immediately.
- c. It has a faster onset of action.
- d. It is always cheaper than the immediate-release form.
Answer: a. If an adverse effect occurs, the drug cannot be easily removed from the body.
40. A pharmacist’s knowledge of dosage forms is critical for preventing medication errors.
- a. True
- b. False
Answer: a. True
41. An example of a medication error related to dosage form would be:
- a. A nurse crushing an extended-release tablet to administer through a feeding tube.
- b. A patient swallowing a sublingual tablet.
- c. A patient cutting a transdermal patch in half.
- d. All of the above.
Answer: d. All of the above.
42. The pharmacokinetic profile of an LAI is characterized by:
- a. A high initial peak followed by a rapid decline.
- b. A slow rise to a steady-state concentration which is then maintained for a prolonged period.
- c. Immediate absorption and elimination.
- d. A flat line with no absorption.
Answer: b. A slow rise to a steady-state concentration which is then maintained for a prolonged period.
43. A patient who has trouble remembering to take a daily pill might be a good candidate for which formulation?
- a. An ODT
- b. A short-acting injection
- c. An oral solution
- d. A long-acting injection
Answer: d. A long-acting injection
44. A pharmacist’s role in counseling on a psychotropic medication must include instructions on:
- a. The specific dosage form and how to use it correctly.
- b. The mechanism of action in detail.
- c. The cost of manufacturing.
- d. The chemical structure.
Answer: a. The specific dosage form and how to use it correctly.
45. Which of the following is NOT a primary reason for developing different formulations?
- a. To improve adherence.
- b. To alter the pharmacokinetic profile.
- c. To meet the needs of special patient populations (e.g., pediatrics, dysphagia).
- d. To make the drug more difficult for pharmacists to dispense.
Answer: d. To make the drug more difficult for pharmacists to dispense.
46. A “loading dose” strategy is often required when initiating an LAI to:
- a. Prevent side effects.
- b. Reach therapeutic concentrations more quickly.
- c. Make the injection less painful.
- d. Test for an allergic reaction.
Answer: b. Reach therapeutic concentrations more quickly.
47. The selection of an appropriate needle size is a critical part of administering an LAI.
- a. True
- b. False
Answer: a. True
48. An extended-release tablet uses technology to:
- a. Speed up the dissolution of the drug.
- b. Control the rate at which the drug is released from the tablet over time.
- c. Make the tablet taste better.
- d. Increase the size of the drug molecule.
Answer: b. Control the rate at which the drug is released from the tablet over time.
49. The overall goal of creating new dosage formulations is to:
- a. Improve the therapeutic utility and safety profile of a drug.
- b. Make more money for the manufacturer.
- c. Complicate the work of a pharmacist.
- d. Use more excipients.
Answer: a. Improve the therapeutic utility and safety profile of a drug.
50. The ultimate reason for a pharmacist to master the knowledge of different dosage formulations is to:
- a. Ensure that each patient receives their medication in the form that is safest, most effective, and most appropriate for their individual needs.
- b. Pass the pharmaceutics exam.
- c. Be able to compound any formulation.
- d. Impress physicians with their knowledge.
Answer: a. Ensure that each patient receives their medication in the form that is safest, most effective, and most appropriate for their individual needs.
